Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Launched by IMAGINE INSTITUTE · Jun 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a group of rare genetic diseases called type I interferonopathies. These conditions cause the immune system to be overactive, leading to inflammation that mainly affects the brain and nervous system, and sometimes the joints and blood cells. These diseases often start in childhood but can also begin in adulthood. Right now, doctors don’t fully understand how these conditions develop over time or how best to treat them. This study aims to learn more about how the disease progresses in both children and adults, to find markers that can help with diagnosis and monitoring, and to eventually develop treatments tailored to different types of patients.

Anyone with a confirmed genetic diagnosis of a type I interferonopathy and who is covered by a social security health plan may be eligible to join the study. Participation involves sharing medical information over time to help researchers track the disease’s course. The study is not yet open for enrollment. If you or a family member are interested, it’s important to know that minors will need permission from a parent or guardian to participate. The goal is to better understand these rare diseases so future treatments can be more effective and personalized.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Genetically confirmed patient with type I interferonopathy
• • Patient affiliated to a social security scheme or beneficiary of such a scheme.
• Exclusion Criteria:
• • - Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.